Supplement for Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Name: Supplement for Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
Creator: Robert Bissonnette
Published: 2025-05-06T18:36:51.241Z
Keywords: Dermatology, Atopic Dermatitis

Bissonnette, Robert; Stein Gold, Linda; Kircik, Leon; Simpson, Eric; Eichenfield, Lawrence F.; Browning, John; Hebert , Adelaide A.; Alexis, Andrew F.; Soong, Weily; Piscitelli, Stephen C.; Tallman, Anna M.; Rubenstein, David S.; Brown, Philip M.; Silverberg, Jonathan

doi:10.17632/s4jfrybx29.1

Supplement for Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Published: 6 May 2025| Version 1 | DOI: 10.17632/s4jfrybx29.1

Contributors:

Robert Bissonnette, Linda Stein Gold, Leon Kircik, Eric Simpson, Lawrence F. Eichenfield, John Browning, Adelaide A. Hebert , Andrew F. Alexis, Weily Soong, Stephen C. Piscitelli, Anna M. Tallman, David S. Rubenstein, Philip M. Brown, Jonathan Silverberg

Description

Supplemental material for the Bissonnette et al. Tapinarof Cream ADORING 3 Phase 3 Long-term Trial in AD article

Files

Funders

Dermavant Sciences, an Organon Company

Supplement for Skin Clearance, Duration of Treatment-free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-week Phase 3 Open-label Extension Trial in Adults and Children Down to 2 Years of Age with Atopic Dermatitis

Description

Files

Categories

Funders

Licence